v3.25.1
Balance Sheet Details (Tables)
 12 Months Ended
Dec. 31, 2024
Balance Sheet Details [Abstract]  
Schedule of Inventories

Inventories, which primarily relate to Proclarix product as of December 31, 2024 and ENTADFI product as of December 31, 2023, consisted of the following:

 

   December 31,
2024		   December 31,
2023		 
Raw materials  $57,446   $139,208 
Work-in-process   
—
    194,805 
Finished goods   6,633    30,039 
Total  $64,079   $364,052 
Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following as of December 31, 2024 and 2023:

 

   December 31,
2024		   December 31,
2023		 
Prepaid insurance  $101,999   $122,004 
Prepaid regulatory fees   
—
    312,551 
Prepaid research and development   
—
    89,195 
Prepaid professional fees   7,487    70,708 
VAT taxes receivable   28,756    
—
 
Prepaid other   33,894    175,695 
Other Receivable   41,835    
—
 
Total  $213,971   $770,153 
Schedule of Intangible Assets

Intangible assets, which were recorded during the year ended December 31, 2023 in connection with the ENTADFI and Proteomedix acquisitions (see Note 5), is comprised of customer relationships, product rights for developed technology and a trade name, and consisted of the following as of December 31, 2024 and 2023:  

 

   Trade name   Product rights
for developed
technology		   Customer
relationships		   Total intangible
assets, net		 
                 
Balance at January 1, 2023  $
-
   $
-
   $
-
   $
-
 
Additions   9,018,000    28,447,771    1,891,000    39,356,771 
Impairment   
-
    (14,610,128)   
-
    (14,610,128)
Amortization   
-
    (31,213)   (5,599)   (36,812)
Effect of Foreign Currency Translation   294,739    344,514    61,803    701,056 
Balance at December 31, 2023  $9,312,739   $14,150,944   $1,947,204   $25,410,887 
Measurement period adjustments related to the Proteomedix acquisition (Note 5)   (6,239,000)   (3,264,000)   (818,000)   (10,321,000)
Impairment   (2,676,441)   (9,912,392)   (987,607)   (13,576,440)
Amortization   (185,396)   (457,144)   (66,502)   (709,042)
Effect of Foreign Currency Translation   (211,902)   (517,408)   (75,095)   (804,405)
Balance at December 31, 2024  $
-
   $
-
   $
-
   $
-
 
Schedule of Goodwill

Goodwill consisted of the following as of December 31, 2024 and 2023: 

 

Balance as of January 1, 2023  $
-
 
PMX transaction goodwill   53,914,055 
Foreign currency translation   1,762,087 
Balance as of December 31, 2023   55,676,142 
Measurement period adjustment related to the Proteomedix acquisition   8,393,843 
Impairment loss   (32,347,000)
Foreign currency translation   (4,674,012)
Balance as of December 31, 2024  $27,048,973 
Schedule of Accrued Expenses

Accrued expenses consisted of the following as of December 31, 2024 and 2023:

 

   December 31,
2024		   December 31,
2023		 
Accrued compensation  $186,956   $487,579 
Accrued research and development   320,096    616,707 
Accrued professional fees   161,981    550,415 
Accrued implementation fees   
—
    93,787 
Accrued franchise taxes   40,000    60,530 
Accrued interest   139,409    
—
 
Accrued deferred offering costs   
—
    125,000 
Accrued license fees   14,705    — 
Other accrued expenses   25,841    265,849 
Total  $        888,988   $        2,199,867